$11.99
0.58% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
ANN6748L1027
Symbol
OFIX

Orthofix International NV Stock price

$11.99
-0.93 7.20% 1M
-6.88 36.46% 6M
-5.47 31.33% YTD
-3.11 20.60% 1Y
-14.83 55.29% 3Y
-22.49 65.23% 5Y
-20.64 63.25% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.07 0.58%
ISIN
ANN6748L1027
Symbol
OFIX
Sector

Key metrics

Market capitalization $469.78m
Enterprise Value $602.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.75
P/S ratio (TTM) P/S ratio 0.58
P/B ratio (TTM) P/B ratio 1.02
Revenue growth (TTM) Revenue growth 5.85%
Revenue (TTM) Revenue $804.53m
EBIT (operating result TTM) EBIT $-98.83m
Free Cash Flow (TTM) Free Cash Flow $-4.95m
Cash position $60.45m
EPS (TTM) EPS $-3.70
P/E forward negative
P/S forward 0.58
EV/Sales forward 0.74
Short interest 2.17%
Show more

Is Orthofix International NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Orthofix International NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Orthofix International NV forecast:

3x Buy
60%
2x Hold
40%

Analyst Opinions

5 Analysts have issued a Orthofix International NV forecast:

Buy
60%
Hold
40%

Financial data from Orthofix International NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
805 805
6% 6%
100%
- Direct Costs 296 296
8% 8%
37%
509 509
5% 5%
63%
- Selling and Administrative Expenses 454 454
2% 2%
56%
- Research and Development Expense 74 74
3% 3%
9%
-19 -19
65% 65%
-2%
- Depreciation and Amortization 80 80
44% 44%
10%
EBIT (Operating Income) EBIT -99 -99
10% 10%
-12%
Net Profit -143 -143
13% 13%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about Orthofix International NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Orthofix International NV Stock News

Neutral
Seeking Alpha
14 days ago
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore - President and Chief Executive Officer Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Caitlin Cronin - Canaccord Genuity Jeffrey Cohen - Ladenburg Oper...
Neutral
Business Wire
15 days ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release e...
Neutral
Business Wire
2 months ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue def...
More Orthofix International NV News

Company Profile

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Head office Curaçao
CEO Massimo Calafiore
Employees 1,616
Founded 1987
Website www.orthofix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today